Somewhat Positive Media Coverage Somewhat Unlikely to Affect Fulgent Genetics (FLGT) Share Price

News coverage about Fulgent Genetics (NASDAQ:FLGT) has trended somewhat positive this week, according to Accern Sentiment Analysis. Accern ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Fulgent Genetics earned a news impact score of 0.19 on Accern’s scale. Accern also gave press coverage about the company an impact score of 46.9976485461397 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

FLGT has been the topic of a number of research analyst reports. Zacks Investment Research raised Fulgent Genetics from a “sell” rating to a “hold” rating in a report on Tuesday, September 12th. Piper Jaffray Companies reaffirmed a “buy” rating on shares of Fulgent Genetics in a report on Tuesday, October 24th. Credit Suisse Group lowered their price target on Fulgent Genetics from $10.00 to $7.50 and set an “outperform” rating on the stock in a report on Tuesday, November 7th. Raymond James Financial downgraded Fulgent Genetics from an “outperform” rating to a “mkt perform” rating in a report on Tuesday, November 7th. Finally, ValuEngine upgraded Fulgent Genetics from a “sell” rating to a “hold” rating in a research report on Monday, October 2nd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the stock. Fulgent Genetics has an average rating of “Hold” and a consensus target price of $7.25.

Shares of Fulgent Genetics (FLGT) opened at $4.38 on Friday. The company has a market capitalization of $75.93 and a price-to-earnings ratio of 211.00. Fulgent Genetics has a 1 year low of $2.72 and a 1 year high of $13.90.

In related news, CEO Ming Hsieh purchased 11,520 shares of Fulgent Genetics stock in a transaction on Thursday, November 9th. The stock was acquired at an average price of $3.47 per share, for a total transaction of $39,974.40. Following the completion of the transaction, the chief executive officer now directly owns 6,506,464 shares in the company, valued at approximately $22,577,430.08. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. In the last quarter, insiders have purchased 33,488 shares of company stock valued at $112,769. 58.80% of the stock is owned by company insiders.

TRADEMARK VIOLATION NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect Fulgent Genetics (FLGT) Share Price” was first reported by Week Herald and is the property of of Week Herald. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The legal version of this report can be accessed at

About Fulgent Genetics

Fulgent Genetics, Inc is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes.

Insider Buying and Selling by Quarter for Fulgent Genetics (NASDAQ:FLGT)

Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with's FREE daily email newsletter.

Leave a Reply